Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from BriaCell Therapeutics ( ...

BridgeBio Pharma (NASDAQ:BBIO) shares surged 15% on Monday after the company announced highly positive Phase 3 results for its small-molecule therapy BBP-418, targeting limb-girdle muscular dystrophy ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in ...

The owner of the shuttered Three Mile Island nuclear power plant said Friday that it plans to restart the reactor under a 20-year agreement that calls for tech giant Microsoft to buy the power to ...

The public will get a chance to provide input to regulators on a Lancaster city data center's proposed second phase, a two-story building expected to total 735,128 square feet and cost as much as $2.5 ...

TURNOUT AT THE CITY MEETING THERE TONIGHT. YEAH, GUYS, CITY OFFICIALS ACTUALLY HAD TO MOVE THE MEETING OUT OF CITY HALL AND HERE TO THIS NEARBY EVENT CENTER TO ACCOUNT FOR THE INFLUX OF PEOPLE FROM ...

SAN FRANCISCO, Oct. 21, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08500 (S.D.N.Y), has been filed after MoonLake (NASDAQ: ...

AB SCIENCE PROVIDES INITIAL PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 16 October 2025, 9pm CET AB Science SA ...

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading lower on Monday. The company shared progress on its lead drug candidate and third-quarter financial results. On Sunday, Summit Therapeutics ...

GLASGOW, Scotland, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Causeway Therapeutics, a clinical-stage biotechnology company developing novel medicines for tendon disease, today announced positive topline data ...

3.6: Vikings quarterback Carson Wentz was ineffective primarily due to the Chargers' pass rush. Wentz finished with 3.6 yards per pass. 117: After taking a back seat last weekend, running back Kimani ...